class action lawsuit

$PSFE plunges 27.6% after missing Q3 revenue by $5.8M, revealing undisclosed high-risk client exposure. Class action securities fraud lawsuit filed.

Class action lawsuit alleges CoreWeave made materially false statements about demand and supplier risks between March-December 2025. Lead plaintiff deadline: March 13, 2026.

PomDoctor faces class action lawsuit alleging securities fraud through social media manipulation, insider stock dumping via offshore accounts, and artificial price inflation. Lead plaintiff deadline: April 6, 2026.

Corcept Therapeutics faces class action lawsuit after FDA rejected relacorilant drug application, triggering 50% stock collapse and disclosure allegations.

Four publicly-traded companies face securities fraud class actions with April 2026 lead plaintiff deadlines. Allegations include false partnership claims, overstated DOE funding, and improper asset valuations.

Class action lawsuit filed against $VTGN alleging securities fraud over fasedienol drug trial statements and concealed adverse clinical data.

NuScale Power faces class action lawsuit after paying $495M to inexperienced nuclear startup ENTRA1, triggering 12.4% stock plunge and investor claims of material risk concealment.

Class action lawsuit alleges BellRing made false statements about sales performance, concealing inventory hoarding as genuine demand. Stock crashed 51.6% total.

Law firm sues China Liberal Education Holdings for failing to disclose pump-and-dump manipulation and non-bona fide transactions, harming investors.

Schall Law Firm seeks $BYND investors for class action alleging false statements about long-lived assets and impairment charges between February-November 2025.

Ardent Health ($ARDT) faces securities fraud lawsuit over alleged false statements on receivables collection and inadequate insurance coverage. Investors urged to join before March 9, 2026.

Enphase Energy faces class action lawsuit over failure to disclose inventory management limitations and tax credit risks. Lead plaintiff deadline: April 20, 2026.

Navan faces securities class action over failing to disclose $95M sales expense surge (39% increase) in Q3 2025. Investors with $100K+ losses have until April 24, 2026 to file.

Corcept Therapeutics faces securities class action after FDA rejected lead drug relacorilant. Stock plummeted 50.4%; lead plaintiff deadline set for April 21, 2026.

Ultragenyx Pharmaceutical faces securities lawsuit after setrusumab trial failure caused 42% stock decline. Lead plaintiff deadline April 6, 2026.

Rosen Law Firm files class action against $LAKE over alleged false statements regarding Pacific Helmets, Jolly divisions. Lead plaintiff deadline April 24, 2026.

Class action lawsuit filed against $BRBR for allegedly concealing that sales growth stemmed from customer inventory accumulation rather than genuine demand, triggering 33% stock plunge.

Class action lawsuit filed against Vistagen Therapeutics after Phase 3 trial failure causes 80% stock plunge. Investors have until March 16, 2026 deadline.

Rosen Law Firm files securities class action against $NAVN, alleging false IPO disclosures about sales expenses. Lead plaintiff deadline set for April 24, 2026.

Class action filed against $BBWI over alleged failure to disclose that adjacencies strategy wasn't delivering growth. Stock plummeted 24.8% after Q3 miss and guidance cut.